Sana Biotechnology, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Sana Biotechnology, Inc. (SANA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 33.19 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 32.99M shares, a 9.91% increase year-over-year.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 30.02M shares, a 12.89% decline year-over-year.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 34.46M shares, a 10.80% increase year-over-year.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 31.10M shares, a 8.75% increase year-over-year.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 26.77M shares, a 6.50% decline from fiscal 2024.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 28.63M shares, a 1.91% decline from fiscal 2023.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 29.19M shares, a 18.74% increase from fiscal 2022.
- Sana Biotechnology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 24.58M shares, a 12.54% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 33.19M shares 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 32.99M shares 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | 26.77M shares 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | 26.85M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 29.14M shares 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 30.02M shares 10-Q · filed 2026-05-11 | ||||
| 2024-12-31 | 28.63M shares 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | 32.97M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 34.56M shares 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 34.46M shares 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 29.19M shares 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | 23.44M shares 10-Q · filed 2024-11-08 | ||||
| 2023-06-30 | 32.07M shares 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 31.10M shares 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 24.58M shares 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | 27.32M shares 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | 28.23M shares 10-Q · filed 2022-08-04 | 28.23M shares 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 28.60M shares 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | 21.84M shares 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | 23.23M shares 10-Q · filed 2022-11-02 | ||||
| 2021-06-30 | 1.55M shares 10-Q · filed 2022-08-04 | 23.98M shares 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 24.74M shares 10-Q · filed 2022-05-10 | 11.29M shares 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | 160.19M shares 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | 156.07M shares 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | 156.34M shares 10-Q · filed 2021-08-04 | 156.34M shares 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | 122.94M shares 10-Q · filed 2021-05-05 | ||||
| 2019-12-31 | 127.92M shares 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |